Search results
Results from the WOW.Com Content Network
Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.Five ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 20.80% and 29.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -17.09% and -22.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for ...
Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 28.16% over the past ...
For premium support please call: 800-290-4726 more ways to reach us
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Change is in the air. A new President-elect and the possibility of an end to the pandemic. Some things, however, will always stay the same.Like small cap biotech stocks skyrocketing following the ...
For premium support please call: 800-290-4726 more ways to reach us